Other Columns

Andree Bates asks the question that perhaps no one wants to consider – is your CEO building up your company …or dragging it down?

Graham Young looks at today's experience when visiting the GP compared to that of yesteryear and asks - are we just too good for our own good?

As new personalized medicine technologies such as next generation sequencing find increased clinical use, two key challenges will emerge, Jeff Elton discusses these new hurdles and also how - and why - you need to overcome them.

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from the patient research series “Living with chronic illness”.

Branding is everywhere, and physicians and medical consumers are now faced with more choices than ever before. But what makes someone choose one brand over another?

Marie Crespo explains that the sustained sales performance required for a customer-led approach can only be achieved by aligning market, talent and sales process.

Rita Numerof explains why you'll need a more nuanced sales approach in this new age of payer supremacy and budget cuts to maximise succes.

Before we dive with a solid splash into the sea of patient considerations, let's stop for a moment to consider the most discrete, the least considered of our four P's - providers.

With the introduction of the Patient Protection and Affordable Care Act and Obama's victory in the 2012 Presidential Elections, Rita Numerof looks at what this will do to the wider healthcare landscape and set a few predictions for the next four years.

Graham Young explores the gradual erosion of pharma sales as a respectable profession, the untrained masses who replaced the experts and what over-reliance on Contract Sales Organisations could be doing to your reputation in the field...

Before jumping back into whatever overall narrative thread I was planning on building through this column, I think this first effort for 2013 should be more of a tone-setting kind of thing. So here's the tone...

This month Kevin Dolgin discusses pharma's innate fear of complexity, and how it prevents the industry from fully realizing the potential of an advanced, dare we say complex, CLM system.